BLOOM TECHNOLOGIES

Their core work

Bloom Technologies is a Belgian MedTech SME developing wearable biosensor devices for maternal and obstetric health monitoring. Their flagship product, WISH (Wearable Integrated System for Early Detection of Preterm Labour), is a sensor-based wearable that monitors physiological signals to detect the onset of premature labour before it becomes an emergency. They progressed from proof-of-concept through full product development under the EU's SME Instrument, indicating a company at the transition point between R&D and commercialization. Their work sits at the intersection of wearable electronics, signal processing, and clinical obstetrics.

What they specialise in

How they've shifted over time

Bloom Technologies has a very narrow but deep trajectory: both H2020 projects (2016–2021) focus entirely on the same product, WISH, moving from feasibility study to full development. There is no detectable shift in topic — the company used the EU SME Instrument precisely as intended, to de-risk and scale a single innovation. This is less an evolution of focus and more a maturation of a single bet: they committed to one product and systematically moved it toward market readiness over five years.

Bloom appears to be a single-product company in the final stages of bringing a maternal health wearable to market; a future collaboration would most likely involve clinical validation, regulatory support, or distribution partnerships rather than new R&D.

How they like to work

Bloom operates exclusively as a project coordinator and, notably, without any recorded consortium partners — both projects were run under the SME Instrument, which is designed for individual companies rather than large consortia. This means they are self-directed innovators accustomed to leading their own development agenda rather than integrating into multi-partner research networks. Working with Bloom likely means engaging them as a technology provider or development partner on their terms, not pulling them into a complex consortium structure.

Bloom Technologies has no recorded H2020 consortium partners, consistent with the solo-company SME Instrument model. Their collaborative footprint is limited to Belgium, and any broader network (clinical partners, distributors, hospitals) would be outside the visible H2020 data.

What sets them apart

Bloom is one of very few SMEs in Belgium with a completed SME Instrument Phase 1 + Phase 2 track record in wearable obstetric monitoring — a highly specific niche that few companies globally address with dedicated hardware. Their positioning is that of a product company rather than a research group: they own IP, have passed EU-level feasibility review, and have received nearly €1.3M specifically to bring this product to market. For any consortium needing a validated wearable maternal health device or a commercialization-stage MedTech partner, Bloom is a rare find in the EU landscape.

Highlights from their portfolio

• WISH (Phase 2)
  At €1,258,994, this is by far their largest project and represents a full product development mandate under the competitive SME Instrument Phase 2, awarded only to companies with strong commercial viability.
• WISH (Phase 1)
  The €50,000 Phase 1 feasibility study that successfully unlocked Phase 2 funding, demonstrating Bloom's ability to articulate a credible business case to EU evaluators.